FDA Can’t Find Efficacy For BioMarin’s Drisapersen
This article was originally published in The Pink Sheet Daily
Executive Summary
On verge of advisory committee meeting, FDA says development program was exemplary, but is disappointed data are inconclusive.
You may also be interested in...
Benefit-Risk Frameworks May Be Coming To US FDA Advisory Committees
Structured assessments, which are currently publicly available only for approved products, could help frame questions for panel discussion of specific drugs under review; FDA also exploring ways to make completed frameworks more readily accessible.
Sarepta's Shadow: BioMarin Mulls Turning The Extraordinary Into A Template
Circumstances of FDA's approval of Sarepta's Exondys 51 approval may give BioMarin reason to appeal the complete response for its Duchenne muscular dystrophy treatment drisapersen – but its high-quality data could preclude success.
Duchenne Development: Six-Minute Walk Losing Favor?
Sarepta relied on the endpoint to get accelerated approval for eteplirsen, but the interim CEO says trials for follow-on products could use walk-run tests or other measures instead.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: